Advertisement
UK markets open in 4 hours 41 minutes

  • NIKKEI 225

    37,784.42
    +155.94 (+0.41%)
     

  • HANG SENG

    17,547.48
    +262.94 (+1.52%)
     

  • CRUDE OIL

    83.80
    +0.23 (+0.28%)
     

  • GOLD FUTURES

    2,345.10
    +2.60 (+0.11%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • Bitcoin GBP

    51,651.32
    +267.02 (+0.52%)
     

  • CMC Crypto 200

    1,391.11
    +8.53 (+0.62%)
     

  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     

  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

AstraZeneca sells rare cancer drug to Sanofi for up $300 mln

Reuters - UK Focus

LONDON, July 27 (Reuters) - AstraZeneca (NYSE: AZN - news) , under pressure from falling sales of older drugs, is selling a medicine for a rare type of cancer to Sanofi (NasdaqGM: GCVRZ - news) as it continues a drive to raise cash by divesting certain assets.

Sanofi's rare diseases unit Genzyme will pay AstraZeneca up to $300 million for global rights to Caprelsa, including an upfront payment of $165 million and further milestone payments based on the drug's performance of up to $135 million, the companies said on Monday.

Caprelsa is currently sold in 28 countries for treating medullary thyroid carcinoma and had sales last year of $48 million.

(Reporting by Ben Hirschler)